PharmaMar presents positive results from a Phase II study of PM1183 in Ewing's sarcoma

PharmaMar (MSE:PHM) has presented positive results from a Phase II study of lurbinectedin in Ewing´s sarcoma at the Connective Tissue Oncology Society´s (CTOS) International Congress that took place in Hawaii from the 8th to the 11th of November. …read more

Source: EurekAlert

(Visited 6 times, 1 visits today)

Popular Posts